## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.97 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($192.07)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Jefferies raises Becton Dickinson stock price target to $220 on deal implications**
- Source: Investing.com India | 20251210T110435 | Bullish | Relevance: 100%
-  Jefferies has increased its price target for Becton Dickinson (NYSE:BDX) to $220 from $215, maintaining a Buy rating, due to implications from its transaction with Waters Corporation. The firm notes that investors are "warming up" to the Waters story, supporting Becton Dickinson's stock, and that the "New BD" remaining business appears to be trading at a "relatively cheap pro forma valuation." This adjustment precedes a webinar to discuss the tax-efficient Reverse Morris Trust structure.

**2. First Trust Advisors LP Has $47.38 Million Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251209T093323 | Somewhat-Bullish | Relevance: 99%
-  First Trust Advisors LP increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 6.3% during the second quarter, valuing their position at $47.38 million. Other institutional investors like Vanguard Group Inc. and T. Rowe Price Investment Management Inc. also significantly increased their holdings in the medical instruments supplier. The article also details recent insider stock sales, analyst ratings, and the company's financial performance, including a recent dividend increase.

**3. Natixis Has $10.33 Million Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251209T130752 | Neutral | Relevance: 99%
- Natixis reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.9% in Q2, ending with 59,997 shares valued at $10.33 million. Despite this, institutional investors collectively own about 86.97% of the medical instruments supplier's stock. Becton, Dickinson recently increased its quarterly dividend to $1.05 per share, resulting in an annualized dividend of $4.20 and a yield of 2.2%.

**4. Jefferies Adjusts PT on Becton, Dickinson and Co. to $220 From $215, Maintains Buy Rating**
- Source: marketscreener.com | 20251210T140412 | Somewhat-Bullish | Relevance: 99%
-  Jefferies has updated its price target for Becton, Dickinson and Co. (BDX) to $220, an increase from its previous target of $215. The firm has also chosen to maintain its "Buy" rating for the medical technology company. This adjustment reflects Jefferies' continued positive outlook on Becton, Dickinson and Co.'s stock performance.

**5. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector**
- Source: Insider Monkey | 20251211T072005 | Bullish | Relevance: 99%
-  Morgan Stanley analyst Patrick Wood increased the price target for Becton, Dickinson and Company (BDX) to $210 from $197, maintaining an Overweight rating due to a positive outlook for the MedTech sector. The analyst cited major product cycles, healthier hospital spending, and low valuations as supporting factors for the industry. BDX reported strong fiscal Q4 2025 revenues of $5.9 billion, an 8.3% YoY growth, and plans to complete the merger of its Biosciences and Diagnostic Solutions (New BD) with Waters Corporation by Q1 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $57.4B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 12.6 |
| Current P/E | 13.4 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.3% to 1.8% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 at 3.3% confirms short-term momentum alignment. AM_20 at 4.0% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.76% (CS: 57) | Neutral |
| RSI_14 | 64.5 | Neutral |
| MACD Histogram | 0.43 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.052x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $200.43
- **Stop Loss:** $192.07 (4.2% risk)
- **Target:** $217.15 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 165
- **Position Value:** $33,070.95
- **Portfolio %:** 33.07%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*